Currently, immune checkpoint inhibitors, which function by inhibiting the PD-1/PD-L1 signaling pathway, have significantly augmented the treatment efficacy for lung cancer, particularly among LUAD patients exhibiting positive PD-L1 expression.6 This evidence concerns the gene CD274 and lung cancer.